Data-Driven Gross-to-Net

Data-Driven Gross-to-Net

Maximize Net-Price Visibility and Predictability

Pharma manufacturers have complex go-to-market models, consisting of an array of payer and channel contracts, patient support programs, government contracts, and other relationships. All of these involve a myriad of fees, discounts, rebates, and other factors including product returns and inventory adjustments which dramatically impact the gross selling price. Pharma Gross-to-Net (GTN) processes identify the true net-price, forecast future discounts, and develop an optimal pricing strategy.

Being able to accurately calculate and forecast accruals is vital to our financial planning process and ability to meet our financial goals.”

Vice President | Finance


GTN Forecasts | GTN Accruals | GTN Analytics

Factors affecting Gross-to-Net pricing in the Pharma Industry

Most pharmaceutical manufacturers struggle with gross-to-net accuracy. Despite their best efforts, finance and accounting teams can wrestle with a variety of hurdles.

The graphic shows a breakdown of factors related to pharmaceutical Gross-to-Net (GTN) forecasting.

Challenges Your Team May Face


Take Control of Accrual Management and Forecast Accuracy

IntegriChain can help you overcome the traditional data, process, and resource-related challenges associated with gross-to-net and net-pricing visibility for pharma manufacturing companies. We are experts at understanding the dependencies gross-to-net has on channel, patient, and payer data.

Our comprehensive approach to pharmaceutical gross-to-net includes:

  • Single partner to manage all of your gross-to-net, contracting, pricing, channel, and patient data needs
  • Accrual management and forecasting solutions for life science manufacturing companies of all size and complexity
  • Advisory services to provide industry best-practices, benchmarking, and analogs
  • Analytics to provide rapid, actionable insight into product profitability

Drive Gross-to-Net Automation

Achieving a confident forecast and clear view into a drug’s true net-price can be a major challenge. This can be due to each department running their own gross-to-net spreadsheets and the almost endless array of fees, discounts, chargebacks, credits, and rebates.

The ICyte Platform makes it easier for the gross-to-net (GTN) forecasters to obtain inputs from key stakeholders such as contracts and pricing, channel partners, and patient support. Teams responsible for areas such as pricing, payer deal-making, and co-pay card programs can also model future business strategies in the same platform where overall gross-to-net forecasts are built, leading to a much easier exchange of critical forecast inputs.

Keys to Pharma Gross-to-Net Automation

GTN Automation Cycle for Accruals & Forecasts

Keys to Gross-to-Net Automation, step by step

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article